FDA Approves REPATHA — Amgen USA Inc.

Amgen announced the FDA approval of its viocumab (Repatha) for a pediatric indication on February 26, promising to expand its lipid-lowering market share against Eli Lilly's Praluent in the adolescents and young adults population. The authorization for 12- to 17-year-olds strengthens the company’s anibody portfolio's commercial footprint beyond high-risk adults, diversifying its revenue stream from primary hypercholesterolemia management.